AMENDMENT TRANSMITTAL LETTER (Small Entity) Applicant(s): Gustavo C. Rodriguez						Docket No. 31162			
<del> </del>		-		Examiner J. Goldberg		Group Art Unit		Group Art Unit 1614	
Invention: PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE  TRANSFORMING GROWTH FACTOR-BETA AND/OR APOPTOSIS IN THE OVARIAN EPITHELIUM									
TO THE ASSISTANT COMMISSIONER FOR PATENTS:  Transmitted herewith is an amendment in the above-identified application.  Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.  A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.  The fee has been calculated and is transmitted as shown below.									
CLAIMS AS AMENDED									
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST # PREV. PAID FOR		-		RATE		ADDITIONAL FEE	
6	-	20 =		0	Х	\$9.0	00	\$0.00	
1	-	3 =		0	X	\$40.	00	\$0.00	
Multiple Dependent Claims (check if applicable)								\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT								\$0.00	
targe Departed company of the amount of the copy of th	posit Account of this sheet is equal to the credit any over of this sheet is early filling fees required the credit and process of the credit and the credit	No. enclosed. to cover the norized to charge payment to Depo enclosed. uired under 37 C	e filing for payme posit According.	ee is enclosed. Int of the following ount No. 18-1942  16. R 1.17. I certify that on 12/5/01 first class ma	2001 this	docum ler 37 C.	ent and with t	d fee is being deposited the U.S. Postal Service a 8 and is addressed to the	
	vith is an ity status vith is an ity status vith is an ity status vith is alculated.  CLAIMS  AFTER  6  1  nt Claims  onal fee it arge Detecopy on the amissione cation or ite copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of additional patent appropriate and area of the copy of the copy of additional patent appropriate and area of the copy of the	Filing March  VENTION OF OVARIA  G GROWTH FACTOR-  TO THE A  with is an amendment in ity status of this applicate and is transfer.  CLAIMS REMAINING AFTER AMENDMENT 6 - 1 -  Int Claims (check if application or credit any over the copy of this sheet is expected and in the amount of the copy of this sheet is expected and filing fees required to a copy of this sheet is expected and in the amount of the copy of this sheet is expected and filing fees required for a copy of this sheet is expected	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY G GROWTH FACTOR-BETA AND/OR A  TO THE ASSISTANT COM  with is an amendment in the above-identifity status of this application has been establish Small Entity status calculated and is transmitted as shown in the company of the company of the company of the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the company of this sheet is enclosed.  In the amount of the cover the cover of the cover of the cover of the cover of this sheet is enclosed.  In the amount of the cover the cover of the co	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY ADMING GROWTH FACTOR-BETA AND/OR APOPTO  TO THE ASSISTANT COMMISSION  With is an amendment in the above-identified applity status of this application has been established as submitted.  Statement to establish Small Entity status under calculated and is transmitted as shown below.  CLAIMS AS AME  CLAIMS REMAINING HIGHEST #  AFTER AMENDMENT PREV. PAID FOR COME.  6 - 20 = 1 - 3 = 1 - 1 - 3 = 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY ADMINISTRATION OF DESCRIPTION	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRO G GROWTH FACTOR-BETA AND/OR APOPTOSIS IN THE OVARIA  TO THE ASSISTANT COMMISSIONER FOR PATENTS  with is an amendment in the above-identified application.  ity status of this application has been established under 37 CFR 1.27 is y submitted.  statement to establish Small Entity status under 37 FR 1.27 is enclose calculated and is transmitted as shown below.  CLAIMS AS AMENDED  CLAIMS REMAINING  AFTER AMENDMENT  PREV. PAID FOR  CLAIMS PRESENT  6 20 = 0 x  1 - 3 = 0 x  TOTAL ADDITIONAL FEE FOR THIS AMEND  Data fee is required for amendment.  In the amount of the copy of this sheet is enclosed.  In the amount of to cover the filing fee is enclosed.  In the amount of to cover the filing fee is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the copy of this sheet is enclosed.  In the amount of the following fees the fill the following fees the fill the following fee	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCT: G GROWTH FACTOR-BETA AND/OR APOPTOSIS IN THE OVARIAN EPI  TO THE ASSISTANT COMMISSIONER FOR PATENTS: with is an amendment in the above-identified application. ity status of this application has been established under 37 CFR 1.27 by a very submitted. statement to establish Small Entity status under 37 FR 1.27 is enclosed. calculated and is transmitted as shown below.  CLAIMS AS AMENDED  CLAIMS REMAINING HIGHEST # NUMBER EXTRA RATE AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT 6 - 20 = 0 x \$9.0 1 - 3 = 0 x \$40.  Int Claims (check if applicable)  TOTAL ADDITIONAL FEE FOR THIS AMENDMENT  TOTAL ADDITIONAL FEE FOR THIS AMENDMENT  In the amount of to cover the filing fee is enclosed. In the amount of to cover the filing fee is enclosed. In the amount of to cover the filing fee is enclosed. In the amount of to cover the filing fee is enclosed. In the amount of the following fees association or credit any overpayment to Deposit Account No. 18-1942 the copy of this sheet is enclosed. additional filing fees required under 37 C.F.R. 1.16. patent application processing fees under 37 CFR 1.17.  Dated: December 5, 2001  I certify that this docum on 12/501 first class mail under 37 C.Assistant Commissioner 20231.  20231.	Filing Date March 21, 2000  VENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THE GROWTH FACTOR-BETA AND/OR APOPTOSIS IN THE OVARIAN EPITHEL  TO THE ASSISTANT COMMISSIONER FOR PATENTS:  with is an amendment in the above-identified application. ity status of this application has been established under 37 CFR 1.27 by a verified / submitted. statement to establish Small Entity status under 37 FR 1.27 is enclosed. calculated and is transmitted as shown below.  CLAIMS AS AMENDED  CLAIMS REMAINING AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT ATE  AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT ATE  CLAIMS (check if applicable)  TOTAL ADDITIONAL FEE FOR THIS AMENDMENT  TOTAL ADDITIONAL FEE FOR THIS AMENDMENT  TOTAL ADDITIONAL FEE FOR THIS AMENDMENT  TOTAL ADDITIONAL FEE Senciosed. In the amount of the copy of this sheet is enclosed. In the amount of the copy of this sheet is enclosed. In the amount of the following fees associated cation or credit any overpayment to Deposit Account No.  To credit any overpayment of the following fees associated cation or credit any overpayment to Deposit Account No.  To credit the this document and on 125/801  To credity that this document and on 125/8	

cc: Gustavo C. Rodriguez

Signature of Person Mailing Correspondence

Raymond N. Nimrod

Typed or Printed Name of Person Mailing Correspondence

## CERTIFICATE OF MAILING

I, Raymond N. Nimrod, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with postage prepaid, in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on December 5, 2001.

Dated: December 5, 2001

Raymond N. Nimrod

Attorney Docket No. 3 Ho2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
GUSTAVO C. RODRIGUEZ

Serial No.: 09/528,963

Filed: March 21, 2000

For: PREVENTION OF OVARIAN CANCER
BY ADMINISTRATION OF PRODUCTS
THAT INDUCE TRANSFORMING
GROWTH FACTOR-BETA AND/OR
APOPTOSIS IN THE OVARIAN
EPITHELIUM

Attorney Docket No. 3 Ho2

FOR STATES PATENT AND TRADEMARK OFFICE

FOR STATES PATENT A

## AMENDMENT AND RESPONSE TO OFFICE ACTION DATED SEPTEMBER 5, 2001

TO: Commissioner For Patents

Washington DC 20231

Sir:

Applicant submits this response to the Office Action dated September 5, 2001.

## AMENDMENTS

## IN THE CLAIMS:

Please amend claim 1 as follows:

--1. (Amended) A method of formulating a [regimen] composition for preventing epithelial ovarian cancer for administration to a human female subject comprising selecting an agent based on its ability to upregulate TGF-β expression in the ovarian epithelium by testing said agent by treating ovarian epithelial cells through exposure to said agent and determining the resulting expression of TGF-β in the treated ovarian epithelial cells.